Skip to content

Management of Perioperative Coagulopathy With Thromboelastometry (ROTEM) in Liver Transplant

Management of Perioperative Coagulopathy With Thromboelastometry (ROTEM) in Liver Transplant

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02239991
Enrollment
100
Registered
2014-09-15
Start date
2014-09-30
Completion date
2016-02-29
Last updated
2014-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Coagulation Disorders, Evidence of Liver Transplantation, Liver Cirrhosis

Keywords

Point of care, perioperative hemostasis, thromboelastometry, bleeding risk, end-stage liver disease, hepatic coagulopathy, whole blood coagulation

Brief summary

A point-of-care bleeding management protocol based on global viscoelastic test (thromboelastometry) can change the amount of blood products used during orthotopic liver transplant.

Detailed description

Patients with liver disease frequently acquire a complex disorder of hemostasis secondary to their disease. The fundamental key to the management of coagulopathy of cirrhotic patient is the knowledge that hepatic dysfunction results in impairment of both pro-hemostatic factors as anti-hemostatic factors in a disproportionate manner which can lead to a clinical picture of both bleeding and thrombosis. Routine tests of coagulation as prothrombin time (PT, INR) and activated partial thromboplastin time (APTT) although prolonged in cirrhotic patients cannot predict bleeding. Global viscoelastic test of whole blood (TEG / ROTEM) produce a dynamic composite image of the entire coagulation process and have the potential to provide clinically relevant information in patients with liver disease allowing rational use of blood products during liver transplantation.

Interventions

Group of cirrhotic bleeding patients that are treated with a bed side, point of care protocol based on thromboelastometry to guide transfusion and manage coagulopathy

Sponsors

Hospital Israelita Albert Einstein
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* all patients from the national list of liver transplant assigned to have their transplant in Hospital Israelita Albert Einstein who gave free and clarified consent term.

Exclusion criteria

* acute liver failure * age under 18 * combined transplant * re transplantation less than 30 days * incomplete medical records, more than 20% of missing data.

Design outcomes

Primary

MeasureTime frameDescription
Units of packed red blood cells (PRBCs)intraoperativeA prospective cohort study based on a point-of care protocol to monitor and manage the coagulopathy based on rotational thromboelastometry (ROTEM) in liver transplant with a historical control. Fifty patients will be managed by ROTEM protocol and will be compared with an equal number of historical controls treated according to the traditional protocol based on clinical and laboratory tests. The aim of this prospective study is to show a reduction in 20% of PRBCs transfusion during liver transplant.

Secondary

MeasureTime frameDescription
mortality30 daysAll patients in interventional group will be followed for a period of 30 days.
SepsisDuring intensive care unitSepsis is defined as the presence (probable or documented) of infection together with systemic manifestations of infection. All patients in interventional group will be followed for a period of 30 days.
Acute respiratory distress syndromeDuring intensive care unitA chest X-ray will be done in all patients and will be followed for a period of 30 days. A chest X-ray can reveal which parts of your lungs have fluid in them
Mechanical ventilationDuring intensive care unitAll patients in interventional group will be followed for a period of 30 days and will be noted the number of days under mechanical ventilation.
Intensive care unitup to 30 daysLength of intensive care unit stay

Countries

Brazil

Contacts

Primary ContactLuiz Henrique Ide Yamauchi, physician
luizyamauchi@gmail.com+55112151-7806

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026